Seeking Alpha

Salix Pharmaceuticals (SLXP +7.3%) shares surge after Q4 results topped expectations and sales...

Salix Pharmaceuticals (SLXP +7.3%) shares surge after Q4 results topped expectations and sales of its Xifaxan gastrointestinal drug picked up significantly during H2 2011. SLXP also guides to at least 25% organic growth in Xifaxan in 2012, with strong growth in January that beat the prior record month of December.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs